Completed PHASE2 INTERVENTIONAL NCT00000807

Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

Sponsor: Bristol-Myers Squibb

Conditions HIV Infections Sarcoma, Kaposi

Interventions Etoposide

Updated 6 times since 2017 Last updated: Oct 27, 2021 Completion: Jul 31, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates HIV Infections and Sarcoma, Kaposi and is currently completed. Bristol-Myers Squibb leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Nov 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Birmingham, United States , Boston, United States , Buffalo, United States , Chicago, United States , Denver, United States , Elmhurst, United States , Indianapolis, United States , Los Angeles, United States , Miami, United States and 4 more locations